Lynne Bui
Directeur/Membre du Conseil chez THARIMMUNE, INC.
Fortune : - $ au 31/05/2024
Profil
Lynne A Bui is the founder of Khloris Biosciences, Inc., Global Cancer Research Institute, GCRI Foundation, Inc. She is currently an Independent Director at Tharimmune, Inc. Her former positions include Chief Medical Officer at Onyx Pharmaceuticals, Inc., Exelixis, Inc., and Intellikine LLC.
She received her undergraduate degree from the University of California, Berkeley and her graduate degree from David Geffen School of Medicine.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
THARIMMUNE, INC.
-.--% | 21/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Lynne Bui
Sociétés | Poste | Début |
---|---|---|
THARIMMUNE, INC. | Directeur/Membre du Conseil | 01/07/2021 |
Khloris Biosciences, Inc.
Khloris Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Khloris Biosciences, Inc. operates as biotechnology company. The firm offers drug discovery, vaccine and cell therapies for treatment and prevention of cancer. The company was founded by Lynne A. Bui and Joseph C. Wu in June 2017 and is headquartered in Mountain View, CA. | Directeur Général | 01/06/2017 |
Global Cancer Research Institute | Fondateur | - |
GCRI Foundation, Inc. | Fondateur | - |
Anciens postes connus de Lynne Bui
Sociétés | Poste | Fin |
---|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Directeur Technique/Scientifique/R&D | - |
Intellikine LLC
Intellikine LLC Pharmaceuticals: MajorHealth Technology Intellikine LLC develops and manufactures small molecule drugs for the treatment of cancer. The company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders. Intellikine was founded on May 2nd, 2007 and is headquartered in La Jolla, CA. | Directeur Technique/Scientifique/R&D | - |
EXELIXIS, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Lynne Bui
University of California, Berkeley | Undergraduate Degree |
David Geffen School of Medicine | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
EXELIXIS, INC. | Health Technology |
THARIMMUNE, INC. | Health Technology |
Entreprise privées | 5 |
---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Intellikine LLC
Intellikine LLC Pharmaceuticals: MajorHealth Technology Intellikine LLC develops and manufactures small molecule drugs for the treatment of cancer. The company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders. Intellikine was founded on May 2nd, 2007 and is headquartered in La Jolla, CA. | Health Technology |
Khloris Biosciences, Inc.
Khloris Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Khloris Biosciences, Inc. operates as biotechnology company. The firm offers drug discovery, vaccine and cell therapies for treatment and prevention of cancer. The company was founded by Lynne A. Bui and Joseph C. Wu in June 2017 and is headquartered in Mountain View, CA. | Commercial Services |
Global Cancer Research Institute | |
GCRI Foundation, Inc. |